Banerjee, R., Richards, A., Midha, S., Afrough, A., Anwer, F., Atanackovic, D., Atrash, S., Bachanova, V., Beitinjaneh, A. M., Ouchveridze, E., Castaneda Puglianini, O., Chhabra, S., Cicero, K. I., Davis, J. A., Dhakal, B., Dima, D., Ferreri, C. J., Forsberg, P. A., Freeman, C. L., … Kaur, G. (2025). Universal driving restrictions beyond 4 weeks appear unnecessary following CAR-T therapy in multiple myeloma. Blood Advances. https://doi.org/10.1182/bloodadvances.2025016131

Bumma, N., Richter, J., Jagannath, S., Lee, H. C., Hoffman, J. E., Suvannasankha, A., Zonder, J. A., Shah, M. R., Lentzsch, S., Baz, R., Maly, J. J., Namburi, S., Pianko, M. J., Ye, J. C., Wu, K. L., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Dhodapkar, M. V. (2024). Linvoseltamab for Treatment of Relapsed/Refractory Multiple Myeloma. Journal of Clinical Oncology, 42(22), 2702–2712. https://doi.org/10.1200/jco.24.01008

Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2024). Risk stratification models overestimate progression risk in contemporary patients with smoldering multiple myeloma. HemaSphere, 8(3). Portico. https://doi.org/10.1002/hem3.61

Gao, L., Kaushik, D., Van Tine, B. A., Ingham, M. A., Attia, S., Meyer, C. F., Schwartz, G. K., Maliakal, P., Baird, J. D., Ma, J., Barrett, R., D’Silva, D., O’Keefe, K., & Kong, R. (2024). Pharmacokinetics of dacarbazine and unesbulin and CYP1A2‐mediated drug interactions in patients with leiomyosarcoma. Clinical and Translational Science, 17(2). Portico. https://doi.org/10.1111/cts.13709

Fu, J., Li, S., Ma, H., Yang, J., Pagnotti, G. M., Brown, L. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2023). The checkpoint inhibitor PD-1H/VISTA controls osteoclast-mediated multiple myeloma bone disease. Nature Communications, 14(1). https://doi.org/10.1038/s41467-023-39769-8

Mohan, M., Shah, N., Luan, D., Monge, J., Forsberg, M., Bhatlapenumarthi, V., Balev, M., Patwari, A., Cheruvalath, H., Bhutani, D., Thanendrarajan, S., Dhakal, B., Zangari, M., Al Hadidi, S., Cooper, D. L., Lentzsch, S., van Rhee, F., D’Souza, A., Szabo, A., … Chakraborty, R. (2023). Teclistamab in Relapsed Refractory Multiple Myeloma: Multi-Institutional Real-World Study. Blood, 142(Supplement 1), 545–545. https://doi.org/10.1182/blood-2023-174875

Najjar, M., McCarron, J., Cliff, E. R. S., Berger, K., Steensma, D. P., Al Hadidi, S., Chakraborty, R., Goodman, A., Anto, E., Greene, T., Sborov, D., & Mohyuddin, G. R. (2023). Adverse Event Reporting in Randomized Clinical Trials for Multiple Myeloma. JAMA Network Open, 6(11), e2342195. https://doi.org/10.1001/jamanetworkopen.2023.42195

Hoffman, J. E., Bumma, N., Richter, J., Dhodapkar, M. V., Lee, H. C., Suvannasankha, A., Houde, C. A., Maly, J. J., Shah, M. R., Baz, R., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Lentzsch, S., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Jagannath, S. (2023). Health-Related Quality of Life (HRQoL) Among Patients with Triple-Class Exposed Relapsed/Refractory Multiple Myeloma (RRMM) Treated with Linvoseltamab in Linker-MM1: Interim Assessment up to 36 Weeks of Treatment. Blood, 142(Supplement 1), 3359–3359. https://doi.org/10.1182/blood-2023-179170

Jagannath, S., Richter, J., Dhodapkar, M. V., Hoffman, J. E., Lee, H. C., Suvannasankha, A., Shah, M. R., Lentzsch, S., Zonder, J. A., Baz, R., Maly, J. J., Namburi, S., Wu, K. L., Pianko, M., Ye, J. C., Silbermann, R., Min, C.-K., Vekemans, M.-C., Munder, M., … Bumma, N. (2023). Patterns of Response to 200 Mg Linvoseltamab in Patients with Relapsed/Refractory Multiple Myeloma: Longer Follow-Up of the Linker-MM1 Study. Blood, 142(Supplement 1), 4746–4746. https://doi.org/10.1182/blood-2023-177968

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Prommis Trial Prospectively Demonstrates the Efficacy of SKY92 Risk Stratification in Newly Diagnosed Multiple Myeloma Patients. Blood, 142(Supplement 1), 3386–3386. https://doi.org/10.1182/blood-2023-180761

Dhodapkar, M. V., Alsina, M., Berdeja, J. G., Patel, K. K., Richard, S., Vij, R., Leleu, X., Egan, D. N., Bergsagel, P. L., Reshef, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Eliason, L., Zhong, X., Greggio, C., Tran, S., … Siegel, D. S. (2023). Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients with Clinical High-Risk Newly Diagnosed Multiple Myeloma (NDMM) with an Inadequate Response to Frontline Autologous Stem Cell Transplantation (ASCT): KarMMa-2 Cohort 2c Extended Follow-up. Blood, 142(Supplement 1), 2101–2101. https://doi.org/10.1182/blood-2023-173970

Hughes, M. S., Leng, S., Chakraborty, R., Bhutani, D., Mapara, M., Raza, S., & Lentzsch, S. (2023). Excellent PFS and OS of Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib, Bendamustine, and Dexamethasone (KBD): A 6.5 Year Follow-up. Blood, 142(Supplement 1), 6576–6576. https://doi.org/10.1182/blood-2023-182842

Biran, N., Dhakal, B., Niesvizky, R., Lentzsch, S., McKay, J. T., Vesole, D. H., Nooka, A. K., Paul, B., Hari, P. N., Stork-Sloots, L., D’Ambrosi, S., Kuiper, R., van Vliet, M., Siegel, D. S., Usmani, S. Z., & van Rhee, F. (2023). Unveiling the Discrepancy in Multiple Myeloma Risk Classification between Clinical Practice and SKY92 Test and the Impact on Survival. Blood, 142(Supplement 1), 2013–2013. https://doi.org/10.1182/blood-2023-181905

Fu, J., Li, S., Liu, G., MA, H., Marcireau, C., Mapara, M., & Lentzsch, S. (2023). Synergistic Anti-Tumor Effects in RAS Mut Multiple Myeloma By Targeting MAP4K2 and RAS Pathways. Blood, 142(Supplement 1), 6618–6618. https://doi.org/10.1182/blood-2023-190740

Mellgard, G., Gilligan, M., Cliff, E. R. S., Bhutani, D., Mohyuddin, G. R., Eisenberger, A., Lentzsch, S., & Chakraborty, R. (2023). Risk Stratification Models Overestimate Progression Risk in Contemporary Patients with Smoldering Multiple Myeloma (SMM). Blood, 142(Supplement 1), 4768–4768. https://doi.org/10.1182/blood-2023-174908

Cicero, K. I., Dlamini, X., Mavengere, Y., Justman, J., Nuwagaba-Biribonwoha, H., Dlamini, M., Ngwenyama, S., Ngcamphalala, C., Low, A., Philip, N. M., El-Sadr, W. M., Sahabo, R., Abreha, T., Temesgen, S., Dlamini, S., Mahlalela, N., Chiuzan, C., Chen, Y., Pan, S. S., … Neugut, A. I. (2023). Prevalence of Monoclonal Gammopathy of Undetermined Significance in Eswatini: A Study of an African Population. Blood, 142(Supplement 1), 4767–4767. https://doi.org/10.1182/blood-2023-172435

Mohyuddin, G. R., Chakraborty, R., Cliff, E. R. S., & Derman, B. A. (2023). Clinician preferences on treatment of smoldering myeloma: a cross-sectional survey. EClinicalMedicine, 65, 102272. https://doi.org/10.1016/j.eclinm.2023.102272

Mckean, M., Chmielowski, B., Butler, M. O., Carvajal, R., Rodon, J., Carlino, M., Kim, K. B., Wise-draper, T., Khan, S., Salama, A. K. S., Moser, J., Reeves, J., Wilner, K. D., Maurer, M., Abed, M., Mitchell, B., Beaupre, D., & Orloff, M. (2023). 1081O ctDNA reduction and clinical efficacy of the darovasertib + crizotinib (daro + crizo) combination in metastatic uveal melanoma (MUM). Annals of Oncology, 34, S651. https://doi.org/10.1016/j.annonc.2023.09.2215

Klausz, K., Gehlert, C. L., Krohn, S., Winterberg, D., Lustig, M., Boje, A. S., Besse, L., Besse, A., Driessen, C., Peipp, M., & Gramatzki, M. (2023). P-198 Impact of blocking the CD47 axis on phagocytosis of myeloma cells treated with CD38 antibodies and proteasome inhibitors. Clinical Lymphoma Myeloma and Leukemia, 23, S144–S145. https://doi.org/10.1016/s2152-2650(23)01816-5

Dhodapkar, M., Bumma, N., Richter, J., Lee, H., Hoffman, J., Suvannasankha, A., Lentzsch, S., Shah, M., Zonder, J., Baz, R., Wu, K. L., Pianko, M., Silbermann, R., Min, C.-K., Vekemans, M.-C. M., Munder, M., Byun, J. M., Lopez, J. M., DeVeaux, M., … Jagannath, S. (2023). P-247 Efficacy and safety of linvoseltamab 200 mg in patients with relapsed/refractory multiple myeloma (RRMM): analysis of the LINKER-MM1 study. Clinical Lymphoma Myeloma and Leukemia, 23, S172. https://doi.org/10.1016/s2152-2650(23)01865-7

Fu, J., Li, S., Ma, H., Liu, G., Mapara, M., & Lentzsch, S. (2023). P-391 Checkpoint inhibitor PD-1H/VISTA mediates its effects on osteoclast cytoskeleton in myeloma bone disease via c-Src/Rac1 signaling. Clinical Lymphoma Myeloma and Leukemia, 23, S256. https://doi.org/10.1016/s2152-2650(23)02009-8

Muehlenbein, C. E., Coombs, C. C., Shah, N. N., Jurczak, W., Woyach, J., Cheah, C. Y., Patel, K., Maddocks, K., Wang, Y., Wang, C., Abhyankar, S., Tsai, D. E., & Eyre, T. A. (2023). POSTER: CT-166 Long-Term Safety With ≥12 Months of Pirtobrutinib in Relapsed/Refractory B-Cell Malignancies. Clinical Lymphoma Myeloma and Leukemia, 23, S229. https://doi.org/10.1016/s2152-2650(23)00883-2

Chakraborty, R., Al Hadidi, S., Scheffer Cliff, E. R., & Mohyuddin, G. R. (2023). Is aggressive treatment of smoldering myeloma the path to curing myeloma? Blood Advances, 7(15), 3932–3935. https://doi.org/10.1182/bloodadvances.2023009658

Brownlie, R. J., Kennedy, R., Wilson, E. B., Milanovic, M., Taylor, C. F., Wang, D., Davies, J. R., Owston, H., Adams, E. J., Stephenson, S., Caeser, R., Gewurz, B. E., Giannoudis, P. V., Scuoppo, C., McGonagle, D., Hodson, D. J., Tooze, R. M., Doody, G. M., Cook, G., … Klein, U. (2023). Cytokine receptor IL27RA is an NF-κB–responsive gene involved in CD38 upregulation in multiple myeloma. Blood Advances, 7(15), 3874–3890. https://doi.org/10.1182/bloodadvances.2022009044

Alsina, M., Dhodapkar, M., Berdeja, J., Patel, K., Richard, S., Vij, R., Leleu, X., Egan, D., Leif Bergsagel, P., Ran, R., Usmani, S. Z., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Zhong, X., Greggio, C., Popa Mckiver, M., Carrasco Alfonso, M., & Siegel, D. (2023). P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN INADEQUATE RESPONSE TO FRONTLINE AUTOLOGOUS STEM CELL TRANSPLANTATION (ASCT): RESULTS FROM KARMMA-2 COHORT 2C. HemaSphere, 7(S3), e90596a3. https://doi.org/10.1097/01.hs9.0000970388.90596.a3

Lee, H. C., Bumma, N., Richter, J., Dhodapkar, M., Hoffman, J. E., Suvannasankha, A., Zonder, J., Shah, M. R., Lentzsch, S., Maly, J. J., Ye, J. C., Wu, K. L., Deveaux, M., Chokshi, D., Boyapati, A., Hazra, A., Lorenc, K. R., Kroog, G., Houvras, Y., & Jagannath, S. (2023). S197: LINKER-MM1 STUDY: LINVOSELTAMAB (REGN5458) IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 7(S3), e1610068. https://doi.org/10.1097/01.hs9.0000967700.16100.68

Di Meo, F., Iyer, A., Akama, K., Cheng, R., Yu, C., Cesarano, A., Kurihara, N., Tenshin, H., Aljoufi, A., Marino, S., Soni, R. K., Roda, J., Sissons, J., Vu, L. P., Guzman, M., Huang, K., Laskowski, T., Broxmeyer, H. E., Roodman, D. G., & Perna, F. (2023). A target discovery pipeline identified ILT3 as a target for immunotherapy of multiple myeloma. Cell Reports Medicine, 4(7), 101110. https://doi.org/10.1016/j.xcrm.2023.101110

Bauer, S., Larkin, J., Hodi, F. S., Stephen, F., Kapiteijn, E. H. W., Schwartz, G. K., Calvo, E., Yerramilli-Rao, P., Piperno-Neumann, S., & Carvajal, R. D. (2023). A phase Ib trial of combined PKC and MEK inhibition with sotrastaurin and binimetinib in patients with metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975642

Chakraborty, R., Yi, J., Rybicki, L., Preussler, J., Deol, A., Loren, A., Savani, B., Jim, H. S. L., Cerny, J., Reynolds, J., Whitten, J., Wingard, J. R., McGuirk, J. P., Uberti, J., Khera, N., Stiff, P., Jaglowski, S. M., Hashmi, S., Holtan, S. G., … Majhail, N. S. (2023). Patient-Reported Outcomes in Long-Term Survivors of Autologous Hematopoietic Cell Transplantation in Multiple Myeloma. Transplantation and Cellular Therapy, 29(6), 388.e1-388.e6. https://doi.org/10.1016/j.jtct.2023.02.011

Fu, J., Li, S., Ma, H., Yang, J., Brown, L. M., Pagnotti, G. M., Weiss, S. J., Mapara, M. Y., & Lentzsch, S. (2022). The Novel Role of Checkpoint Inhibitor PD-1H/VISTA in Osteoclast Cytoskeleton Regulation and Multiple Myeloma Bone Disease. Blood, 140(Supplement 1), 9930–9932. https://doi.org/10.1182/blood-2022-169921

Usmani, S., Patel, K., Hari, P., Berdeja, J., Alsina, M., Vij, R., Raje, N., Leleu, X., Dhodapkar, M., Reshef, R., Truppel-Hartmann, A., Basudhar, D., Thompson, E., Zheng, X., Ananthakrishnan, R., Greggio, C., Favre-Kontula, L., Sternas, L., & San-Miguel, J. (2022). KarMMa-2 Cohort 2a: Efficacy and Safety of Idecabtagene Vicleucel in Clinical High-Risk Multiple Myeloma Patients with Early Relapse after Frontline Autologous Stem Cell Transplantation. Blood, 140(Supplement 1), 875–877. https://doi.org/10.1182/blood-2022-162469

Granat, L. M., Li, H., Anwer, F., Sheu, M., Faiman, B. M., Khouri, J., Mazzoni, S., Valent, J., Samaras, C. J., Chakraborty, R., Chaulagain, C. P., van Heeckeren, W. J., & Williams, L. S. (2022). Hypercalcemia: A Risk Factor for Early Disease Progression and Poor Survival in Cytogenetically Standard-Risk Multiple Myeloma. Blood, 140(Supplement 1), 4290–4291. https://doi.org/10.1182/blood-2022-168040

Naqvi, S. A. A., Fatima, S., Asghar, N., Ijaz, H., Ayaz, A., He, H., Husnain, M., Chakraborty, R., Riaz, I., & Aljama, M. A. (2022). Post Autologous Stem Cell Transplant Maintenance in Patients with Newly Diagnosed Multiple Myeloma: A Network Meta-Analysis. Blood, 140(Supplement 1), 10111–10113. https://doi.org/10.1182/blood-2022-170869

Bumma, N., Richter, J., Brayer, J., Zonder, J. A., Dhodapkar, M., Shah, M. R., Hoffman, J. E., Mawad, R., Maly, J. J., Lentzsch, S., Suvannasankha, A., Roy, P., Dey, J., Chokshi, D., Boyapati, A., Visich, J., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., & Jagannath, S. (2022). Updated Safety and Efficacy of REGN5458, a BCMAxCD3 Bispecific Antibody, Treatment for Relapsed/Refractory Multiple Myeloma: A Phase 1/2 First-in-Human Study. Blood, 140(Supplement 1), 10140–10141. https://doi.org/10.1182/blood-2022-159969

Shah, N. N., Wang, M. L., Brown, J. R., Patel, K., Woyach, J. A., Wierda, W. G., Ujjani, C. S., Eyre, T. A., Zinzani, P. L., Alencar, A. J., Gastinne, T., Ghia, P., Lamanna, N., Hoffmann, M., Patel, M. R., Flinn, I. W., Gerson, J. N., Ma, S., Coombs, C. C., … Mato, A. R. (2022). Safety and Tolerability of Pirtobrutinib Monotherapy in Patients with B-Cell Malignancies Who Were Previously Intolerant to a Covalent BTK Inhibitor: Results from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 4127–4132. https://doi.org/10.1182/blood-2022-159035

Mohyuddin, G. R., Chakraborty, R., Calip, G., Ascha, M. S., Wang, X., Rubinstein, S., Tuchman, S. A., Costa, L. J., Haaland, B., Giri, S., Mian, H. S., Fonseca, R., & Sborov, D. W. (2022). Prognostic Value of Translocation 11;14 in Patients with Relapsed/Refractory Myeloma Receiving Anti-CD38 Therapy. Blood, 140(Supplement 1), 5223–5224. https://doi.org/10.1182/blood-2022-165541

McCurdy, A., Seow, H., Pond, G. R., Gayowsky, A., Chakraborty, R., Visram, A., Kaedbey, R., D’Souza, A., Mohyuddin, G. R., Fonseca, R., & Mian, H. S. (2022). Causes of Death Among Patients with Multiple Myeloma: A 10 Year Longitudinal Analysis of a Population-Based Cohort in Ontario, Canada. Blood, 140(Supplement 1), 427–429. https://doi.org/10.1182/blood-2022-157815

Chakraborty, R., Sexton, R., Lentzsch, S., Abidi, M. H., Voorhees, P. M., Cohen, A. D., Rohren, E., Heitner, S. B., Kelly, K. R., Mackler, N. J., Baer, D. M., Hoering, A., Durie, B. G. M., Ailawadhi, S., & Orlowski, R. Z. (2022). Renal Toxicity with Carfilzomib in Multiple Myeloma: Secondary Analysis of SWOG S1304 Comparing Low-Dose Versus High-Dose Carfilzomib. Blood, 140(Supplement 1), 4349–4351. https://doi.org/10.1182/blood-2022-166609

Li, S., Fu, J., Yang, J., Ma, H., Mapara, M. Y., Marcireau, C., & Lentzsch, S. (2022). MAP4K2 Inhibition Reinforces the Iberdomide Sensitivity in MM Cells By Inducing IKZF1 Degradation through a CRBN Independent Mechanism. Blood, 140(Supplement 1), 4224–4225. https://doi.org/10.1182/blood-2022-168314

Zhou, P., Mansukhani, M. M., Toskic, D., Scalia, S., Lee, L., Wong, S. W., Tuchman, S. A., Hoffman, J. E., Fogaren, T., Varga, C., Lentzsch, S., & Comenzo, R. (2022). Next Generation Sequencing Identifies Light-Chain Amyloid (AL)-Related Igvl Genes in Patients with λ Monoclonal Gammopathy of Undetermined Significance (MGUS) or Smoldering Multiple Myeloma (SMM). Blood, 140(Supplement 1), 10048–10049. https://doi.org/10.1182/blood-2022-157790

Baljevic, M., Gasparetto, C., Schiller, G. J., Tuchman, S. A., Callander, N. S., Lentzsch, S., Monge, J., Kotb, R., Bahlis, N. J., White, D., Chen, C. I., Sutherland, H. J., Madan, S., LeBlanc, R., Sebag, M., Venner, C. P., Bensinger, W. I., Biran, N., DeCastro, A., … Lipe, B. (2022). Selinexor‐based regimens in patients with multiple myeloma after prior anti‐B‐cell maturation antigen treatment. EJHaem, 3(4), 1270–1276. Portico. https://doi.org/10.1002/jha2.572

Carvajal, R. D., Butler, M. O., Shoushtari, A. N., Hassel, J. C., Ikeguchi, A., Hernandez-Aya, L., Nathan, P., Hamid, O., Piulats, J. M., Rioth, M., Johnson, D. B., Luke, J. J., Espinosa, E., Leyvraz, S., Collins, L., Goodall, H. M., Ranade, K., Holland, C., Abdullah, S. E., … Sato, T. (2022). Clinical and molecular response to tebentafusp in previously treated patients with metastatic uveal melanoma: a phase 2 trial. Nature Medicine, 28(11), 2364–2373. https://doi.org/10.1038/s41591-022-02015-7

Khan, S., Patel, S. P., Shoushtari, A. N., Ambrosini, G., Cremers, S., Lee, S., Franks, L., Singh-Kandah, S., Hernandez, S., Sender, N., Vuolo, K., Nesson, A., Mundi, P., Izar, B., Schwartz, G. K., & Carvajal, R. D. (2022). Intermittent MEK inhibition for the treatment of metastatic uveal melanoma. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.975643

Ryu, Y. K., Ricker, E. C., Soderquist, C. R., Francescone, M. A., Lipsky, A. H., & Amengual, J. E. (2022). Targeting CD38 with Daratumumab Plus Chemotherapy for Patients with Advanced-Stage Plasmablastoid Large B-Cell Lymphoma. Journal of Clinical Medicine, 11(16), 4928. https://doi.org/10.3390/jcm11164928

Zonder, J. A., Richter, J., Bumma, N., Brayer, J., Hoffman, J. E., Bensinger, W. I., Wu, K. L., Xu, L., Chokshi, D., Boyapati, A., Cronier, D., Houvras, Y., Rodriguez Lorenc, K., Kroog, G. S., Dhodapkar, M. V., Lentzsch, S., Cooper, D., & Jagannath, S. (2022). S189: EARLY, DEEP, AND DURABLE RESPONSES, AND LOW RATES OF CRS WITH REGN5458, A BCMAXCD3 BISPECIFIC ANTIBODY, IN A PHASE 1/2 FIRST-IN-HUMAN STUDY IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA. HemaSphere, 6, 90–91. https://doi.org/10.1097/01.hs9.0000843648.44771.79